This phase 1/2 clinical study was designed to assess the immunogenicity , safety , and tolerability of a 4-dose series of the rLP2086 vaccine at 20 - , 60 - , 120 - , or 200-g dose levels in vaccine-naive infants when given with routine childhood vaccines .